InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team and Founders
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Facilities
    • Methamphetamine Use Statistics
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

InterveXion’s First IND Application Becomes Active

Apr 12, 2012 | Anti-METH ch-mAb7F9, Uncategorized

An IND for InterveXion’s chimeric anti-METH monoclonal antibody, ch-mAb7F9, was submitted to FDA in March and became active in early April. Plans for the Phase 1a clinical study in healthy volunteers are being finalized and we expect to begin screening potential...

Recent Posts

  • STAMPOUT study to be conducted in METH users when funded
  • InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction
  • InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users
  • InterveXion publishes results of Phase 1a study of ch-mAb7F9
  • Anti-METH Antibody Shortens the Time Rats are Affected by Repeated Doses of METH

Recent Comments

    Archives

    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH ch-mAb7F9
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • RSS

    Designed by Elegant Themes | Powered by WordPress